Celcuity Stock (NASDAQ:CELC)
Previous Close
$12.47
52W Range
$11.51 - $22.19
50D Avg
$15.10
200D Avg
$16.39
Market Cap
$474.52M
Avg Vol (3M)
$290.57K
Beta
0.75
Div Yield
-
CELC Company Profile
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
CELC Performance
Peer Comparison
Ticker | Company |
---|---|
ANAB | AnaptysBio, Inc. |
CYT | Cyteir Therapeutics, Inc. |
DBTX | Decibel Therapeutics, Inc. |
IKNA | Ikena Oncology, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
CSBR | Champions Oncology, Inc. |
ANTX | AN2 Therapeutics, Inc. |
CCCC | C4 Therapeutics, Inc. |
MNOV | MediciNova, Inc. |
RZLT | Rezolute, Inc. |
HOWL | Werewolf Therapeutics, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
ADAG | Adagene Inc. |
MOLN | Molecular Partners AG |